United States · Platforms & data · MarketBeat
Anika Therapeutics' (ANIK) "Buy" Rating Reiterated at B. Riley Financial

Detailed summary
B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)



